A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms DoRIS
- 06 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2017 Status changed from not yet recruiting to recruiting.
- 19 Jun 2017 Planned End Date changed from 1 Aug 2020 to 1 Mar 2021.